Click Therapeutics adds Lee Shapiro to its Board of Directors alongside Dr. Muzammil Mansuri named Board Chair

– USA, NY –  Click Therapeutics, Inc., a leader in Digital Therapeutics as prescription medical treatments, today announced the appointment of accomplished digital healthcare executive Lee Shapiro to its Board of Directors, while former biopharmaceutical executive Dr. Muzammil Mansuri has expanded his role with his appointment as Board Chair.

The company also announced that Wall Street veteran Randall Stanicky has joined as CFO.

These additions further position the organization for continued growth and advancing its mission to develop and commercialize software as treatments.

;“We are honored to have these industry experts on the Click team,” said co-founder and CEO, David Benshoof Klein. “As we discover, develop and commercialize a broad pipeline of prescription digital therapeutics for the treatment of multiple medical conditions, the experience and respected tenures of Randall, Lee, and Muz solidify Click’s leadership role in digital therapeutics and in the broader digital health space.”

About Lee Shapiro

Lee Shapiro joins Click’s Board of Directors and will serve as chair of the audit committee. He is Managing Partner at 7wireVentures, an investment firm he co-founded over a decade ago. He recently served as CFO of Livongo Health until their successful $18.5B merger with Teladoc. Before Livongo, Mr. Shapiro was President of Allscripts from 2001 until the end of 2012. He has also served on the Board of Directors of leading health technology companies such as Medidata, ConsejoSano, Medisafe, HomeThrive, and other 7wire portfolio companies. He is a member of the National Board of Directors of the American Heart Association, where he chairs the audit committee and serves on the business operations committee.

Lee Shapiro said, “I have had the privilege to work with and evaluate numerous organizations seeking to advance the future of digital health. Click is uniquely positioned to seize on this moment to provide a new type of digital care. I am thrilled to join the Board to help ensure the company succeeds in this opportunity, and to become an investor in the company along with my business partner Glen Tullman.”

He holds a J.D. from The University of Chicago Law School and a B.S. in accounting from the University of Illinois.

About Dr. Muzammil Mansuri

Dr. Muzammil Mansuri has expanded his role from Senior Strategic Advisor to Click’s Board to Chair of the Board. With over three decades of comprehensive experience in senior roles within the global biopharmaceutical industry, Dr. Mansuri’s deep knowledge of therapeutic and digital approaches to patient care is key as Click advances an industry-leading digital therapeutics pipeline. Dr. Mansuri currently serves as a Partner at F-Prime Capital. Before joining F-Prime, Dr. Mansuri was a member of the Executive Committee at Sanofi, as EVP, Strategy, Business Development, and Licensing. Before this, he was at Gilead Sciences as SVP, Research, and Development Strategy and Business Development. In that capacity, he led the R&D Strategy, Business Development, and M&A activities for the company. Dr. Mansuri has served as CEO of several biotech companies and as a General Partner at Flagship Ventures. He began his career in the pharmaceutical industry as a bench medicinal chemist with Bristol Myers.

Board Chair Dr. Mansuri said, “Clinically validated digital therapeutics are the real solutions needed to improve patients’ health outcomes beyond what we have been able to achieve with pharmacotherapy alone. In a time when obtaining access to comprehensive care can be more difficult than ever, Click is positioned to change this paradigm.”

He received his B.Sc. and Ph.D. in chemistry from the University College London and conducted postdoctoral research at UCLA and Columbia University.

About Randall Stanicky

Randall Stanicky joins as CFO with more than 20 years of extensive industry experience and most recently leading RBC Capital Markets’ large-cap, specialty, and generic pharmaceuticals team. Randall Stanicky brings the focused financial leadership necessary to expand Click’s clinical and commercial reach. Before RBC, Stanicky spent the majority of his Wall Street career in a similar role at Goldman Sachs. He holds a Bachelor of Commerce degree from the University of British Columbia and sits on the Board of Directors at the Children’s Tumor Foundation where he serves as an officer and chair of the audit committee.

“The transformative potential of digital therapeutics and the breadth of Click’s platform is what drew me to the company,” said Randall Stanicky. “With clear opportunities to scale the organization and improve clinical outcomes in millions of users, the executive team and I are primed to succeed with our vision.”

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics enable change within individuals and are designed to be used independently or in conjunction with biomedical treatments. The Cliometrics adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program has recently entered a pivotal, fully remote, randomized, controlled trial on the Verily platform for the treatment of Major Depressive Disorder in up to 540 adults.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.